Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT06557161RecruitingPhase 2
Stem cell transplant with TBI or TMLI for adult ALL
This trial tests two different conditioning regimens (total body irradiation or total marrow/lymphoid irradiation) before a stem cell transplant from a matched sibling donor for adults with acute lymphoblastic leukemia (ALL) that is in remission. The goal is to see which regimen works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06531018RecruitingPhase 1/Phase 2
Eltrombopag for newly diagnosed ITP patients
This trial tests if eltrombopag, a medication that helps the body make more platelets, works as the first treatment for people newly diagnosed with immune thrombocytopenia (ITP, a condition where the immune system destroys platelets, causing bleeding problems). It may help raise your platelet count and reduce bleeding risk.
DhakaAges 18–70 - NCT06559345RecruitingPhase 2
Stem cell transplant study for children with ALL in remission
This trial tests a stem cell transplant using a half-matched family donor for children with acute lymphoblastic leukemia (ALL) that is in remission. It compares two different types of radiation conditioning to prepare the body for the new cells, with the goal of improving outcomes.
Zhengzhou, HenanAges 1–17 - NCT06564545RecruitingPhase 2
Radiation-based transplant preparation for adult ALL
This trial studies a new way to prepare adults with ALL for a stem cell transplant from a half-matched family donor. It compares two types of radiation-based conditioning to see which works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT03647852Recruiting
Study for difficult IgA vasculitis with gut symptoms
This study looks at treatment strategies for children with IgA vasculitis (also called Henoch-Schönlein purpura) when it mainly affects the stomach and intestines and symptoms do not improve with standard steroid dosing. It may help find better ways to control the illness early and prevent serious complications.
ShanghaiAges 2–16 - NCT06151119Recruiting
PET scan test for myelofibrosis using a special tracer
This study uses a new type of PET/CT scan with a tracer called 68Ga-FAPI to help diagnose myelofibrosis, see how advanced it is, and check if treatment is working. It may help doctors better understand your condition and plan your care.
Xiamen, FujianAges 18 years+ - NCT05603884RecruitingPhase 2
New treatment plan for older adults with newly diagnosed AML
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Xiamen, FujianAges 60 years+ - NCT06151080RecruitingPhase 2
Lenalidomide plus G-CHOP for new DLBCL with follicular lymphoma
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
Xiamen, FujianAges 18–70 - NCT06151106RecruitingPhase 2
Study of Chidamide and Duvalisib for Relapsed or Resistant T-Cell Lymphoma
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Xiamen, FujianAges 18–75 - NCT06158399RecruitingPhase 2
Combination therapy for a specific type of lymphoma
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Xiamen, FujianAges 18–70 - NCT06158412RecruitingPhase 2
ATRA plus KPD for relapsed or refractory multiple myeloma
This trial tests a combination of all-trans retinoic acid (a form of vitamin A) with a chemotherapy regimen called KPD for patients whose multiple myeloma has come back or is not responding to standard treatments. The goal is to see if this combination can help control the disease.
Xiamen, FujianAges 18 years+ - NCT06833827Recruiting
Clot removal vs clot-busting drugs for severe lung clots
This study compares two ways to treat a large blood clot in the lungs that is causing life-threatening symptoms. One method uses a device to remove the clot, the other uses medicine to dissolve it.
Leiden, South HollandAges 18 years+ - NCT06779435Recruiting
Tucidinostat-based treatment for untreated DLBCL
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06660446Recruiting
Exercise during chemo for lymphoma patients
This study tests whether a personalized exercise program during chemotherapy can help people with lymphoma feel stronger and have fewer side effects. You would take part in supervised exercise sessions twice a week for 20 weeks.
Vitoria - Gateiz, ArabaAges 18 years+ - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT05325099RecruitingPhase 1/Phase 2
Azacitidine to help prevent kidney injury after heart surgery
This early-phase study tests whether azacitidine (a medication that changes how cells read genes) can lower the risk of acute kidney injury after cardiac surgery, especially in people already at risk along the chronic kidney disease (CKD) pathway. It aims to protect kidney function during the vulnerable period after surgery.
TaipeiAges 20 years+ - NCT05755867Recruiting
Global registry for people with paroxysmal nocturnal hemoglobinuria
This trial is a global patient registry that collects health information from people diagnosed with PNH (a blood condition caused by a genetic change in the PIG-A gene). It may help researchers better understand the condition and what care people receive.
Bethesda, MarylandAges Any age - NCT07381179Recruiting
Sharing wisdom and hope with illness
This study invites people with a long-term illness to record their stories and wisdom. You can bring a caregiver if you want. It's about giving hope and sharing experiences.
Rochester, MinnesotaAges 18 years+ - NCT07384039Recruiting
Exercise training for people with MPN blood cancers
This study tests whether a regular exercise program can improve health and well-being for people with myeloproliferative neoplasms (a group of blood cancers). It is designed to help you feel stronger and manage your condition better.
Hanover, Lower SaxonyAges 18 years+ - NCT07381426RecruitingPhase 3
Ferric Citrate for Iron Deficiency Anemia in Pregnancy
This trial tests a medication called ferric citrate to treat moderate to severe iron-deficiency anemia during pregnancy. If you qualify, you would take the study pill and have regular check-ups to see if it helps raise your iron levels safely.
DhakaAges 18–35 - NCT07384897Recruiting
Immune cells in lung cancer and chronic lung disease
This study looks at how immune cells work in lung cancer and chronic lung diseases. It aims to find better ways to treat these conditions by studying immune cells from blood, bone marrow, or lung samples.
BrusselsAges Up to 80 years - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.